The emerging safety profile of JAK inhibitors in rheumatic disease

Nature Reviews Rheumatology 13, 234 (2017). doi:10.1038/nrrheum.2017.23 Author: Kevin L. Winthrop Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment of rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently being tested in phase II and III trials for the treatment of a variety of autoimmune inflammatory diseases.
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Tags: Review Source Type: research